Georgios Tsaousis
Overview
Explore the profile of Georgios Tsaousis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nikolaidi A, Papadopoulou E, Haidopoulos D, Liontos M, Fountzilas E, Tsaousis G, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518021
Background: Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) and adjuvant chemotherapy is a therapeutic choice for women with advanced ovarian cancer. Whether NACT affects the tumor's molecular profile...
2.
Papadopoulou E, Rigas G, Fountzilas E, Boutis A, Giassas S, Mitsimponas N, et al.
JCO Precis Oncol
. 2024 Jan;
8:e2300332.
PMID: 38271656
Purpose: The pan-cancer presence of microsatellite instability (MSI)-positive tumors demonstrates its clinical utility as an agnostic biomarker for identifying immunotherapy-eligible patients. Additionally, MSI is a hallmark of Lynch syndrome (LS),...
3.
Fountzilas E, Papadopoulou K, Chatzikonstantinou T, Karakatsoulis G, Constantoulakis P, Tsantikidi A, et al.
Cancers (Basel)
. 2023 Dec;
15(23).
PMID: 38067228
Our aim was to evaluate the concordance between the Myriad MyChoice and two alternative homologous recombination deficiency (HRD) assays (AmoyDx HRD Focus NGS Panel and OncoScan™) in patients with epithelial...
4.
Tsantikidi A, Papazisis K, Floros T, Gazouli M, Papadopoulou E, Tsaousis G, et al.
Oncol Lett
. 2023 Oct;
26(5):480.
PMID: 37809048
Tumors harboring homologous recombination deficiency (HRD) are considered optimal candidates for poly(ADP-ribose) polymerase 1 (PARP) inhibitor treatment. Such deficiency can be detected by analyzing breast cancer type ( gene mutations,...
5.
Tsantikidi A, Papadopoulou E, Metaxa-Mariatou V, Kapetsis G, Tsaousis G, Meintani A, et al.
Diagnostics (Basel)
. 2023 Sep;
13(18).
PMID: 37761329
Several tumor types have been efficiently treated with PARP inhibitors (PARPis), which are now approved for the treatment of ovarian, breast, prostate, and pancreatic cancers. The genes and mutations in...
6.
Papadopoulou E, Pepe G, Konitsiotis S, Chondrogiorgi M, Grigoriadis N, Kimiskidis V, et al.
J Neurol Sci
. 2023 Mar;
447:120609.
PMID: 36905813
Technological advancements have facilitated the availability of reliable and thorough genetic analysis in many medical fields, including neurology. In this review, we focus on the importance of selecting the appropriate...
7.
Ozdogan M, Papadopoulou E, Tsoulos N, Tsantikidi A, Mariatou V, Tsaousis G, et al.
BMC Med Genomics
. 2021 Apr;
14(1):105.
PMID: 33853586
Background: Tumor molecular profile analysis by Next Generation Sequencing technology is currently widely applied in clinical practice and has enabled the detection of predictive biomarkers of response to targeted treatment....
8.
Gourgouli K, Gourgouli I, Tsaousis G, Spai S, Niskopoulou M, Efthimiopoulos S, et al.
Int Ophthalmol
. 2020 Jan;
40(4):985-997.
PMID: 31916060
Purpose: To determine whether gene polymorphisms which are associated with age-related macular degeneration (AMD) influence treatments' response and specifically the antioxidant supplementation in dry AMD patients, as well as the...
9.
Papadopoulou E, Tsoulos N, Tsantikidi K, Metaxa-Mariatou V, Stamou P, Kladi-Skandali A, et al.
PLoS One
. 2019 Dec;
14(12):e0226853.
PMID: 31860648
Background: Analysis of circulating tumor nucleic acids in plasma of Non-Small Cell Lung Cancer (NSCLC) patients is the most widespread and documented form of "liquid biopsy" and provides real-time information...
10.
Tsoulos N, Papadopoulou E, Metaxa-Mariatou V, Tsaousis G, Efstathiadou C, Tounta G, et al.
Oncol Rep
. 2017 Nov;
38(6):3419-3429.
PMID: 29130105
Non‑small cell lung cancer (NSCLC) is the most common type of lung cancer and a tumor with a broad spectrum of targeted therapies already available or in clinical trials. Thus,...